CGTLive’s Weekly Rewind – January 27, 2023

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. 10 Cell and Gene Therapies to Watch in 2023

With confidence building, numerous cell and gene therapies will likely go before the FDA and other global regulatory agencies this year, in addition to key data readouts.

2. Diane Simeone, MD, on Screening Patients for CAR-T Eligibility Before Solid Tumor Relapse

Simeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.

3. Discogenic Progenitor Cell Therapy Shows Improvements in Lumbar Degenerative Disc Disease, Recognized by FDA

The DGX-A01 study met its primary safety and efficacy endpoints in its highest dose cohort of IDCT.

4. Adam Cuker, MD, on Higher Efficacy of Gene Therapy Over SOC in Hemophilia B

The associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogeneelaparvovec.

5. Lifileucel Creeps Closer to Clinic for Melanoma, NSCLC

Iovance is on track to complete its rolling BLA submission for lifileucel in the post-anti-PD1 melanoma indication in the first quarter of 2023.